Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Orion Pharma
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
Safety and pharmacokinetics of ODM-204 in patients with metastatic castration -resistant prostate cancer: an open-label, non - randomised, uncontrolled, multicentre, dose escalation, first-in- man study with additional expansion phase with a dose selected in the escalation phase Ensimmäisen vaiheen turvallisuus- ja imeytymistutkimus ODM-204 valmisteella kastraatiohoitoon reagoimattomilla eturauhassyöpäpotilailla: avoin, satunnaistamaton, kontrolloimaton, nousujohteiseen annoksen nostoon perustuva monikeskus- ja annoslaajennustutkimus
To evaluate safety and tolerability of ODM-204 including dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD), if possible
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION STUDY TO STUDY 3104001
The primary objective of this extension study is to gain more information about the long-term safety and tolerability of ODM-201.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
Update Il y a 4 ans
Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients
to provide efficacy data of the direct switch from levodopa/carbidopa or levodopa/benserazide to levodopa/carbidopa/entacapone (Stalevo®) by clinical global impression of change (CGI-C) as judged by t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study
To compare the effect of Stalevo 200 and Sinemet on the change of striatal (butaminal and caudate) 11C-raclopride binding potential (BP) from baseline in PD patients with wearing-off symptoms.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
First in human study with ODM-207 in patients with selected advanced cancers to assess its safety and how the body affects it
Part 1: To evaluate the safety and tolerability, define the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) if possible, and define the recommended doses and dosing schedules of ODM...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 15 years
and 99 years
Orion Pharma
Update Il y a 4 ans
Étude BETIDES : étude de phase 1 / 2 visant à évaluer la sécurité d’emploi, la tolérance et la pharmacocinétique de l’ODM-207 chez des patients ayant des tumeurs solides avancées. [essai clos aux inclusions]
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquents puisque, à eux seuls, ils représentent 90% des cancers humains. Dan...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Studio multinazionale, randomizzato, in doppio cieco, controllato con placebo, di Fase III, per valutare l’efficacia e la sicurezza di ODM-201 in pazienti di sesso maschile con cancro della prostata resistente alla castrazione non metastatico ad alto rischio
The primary objective of this study is to demonstrate the superiority of ODM-201 vs. placebo in metastasis free survival (MFS) in patients with high-risk nmCRPC
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Orion Pharma
Update Il y a 4 ans
Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
Primary objective is to test the hypothesis that levosimendan is superior to placebo in the composite endpoint called “Patient Journey” during the 60 days following randomisation.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3